Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Decitabine and Cedazuridine + Eltanexor |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Decitabine and Cedazuridine | Inqovi | ASTX-727|ASTX 727|ASTX727 | Chemotherapy - Antimetabolite 14 | Inqovi (decitabine and cedazuridine) is a combination of decitabine and cedazuridine, which may inhibit proliferation of tumor cells (PMID: 30926081). Inqovi (decitabine and cedazuridine) is an FDA approved chemotherapy agent (FDA.gov). |
Eltanexor | KPT-8602 | Eltanexor (KPT-8602) inhibits exportin-1 (XPO1), resulting in decreased nuclear export and potentially resulting in increased tumor cell death (PMID: 27780859). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05918055 | Phase Ib/II | Decitabine and Cedazuridine + Eltanexor | Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes | Recruiting | USA | 0 |